Abbelight Raises Series B Funding To Expand Imaging Solutions And Customer Reach

Founded in 2016 by CEO Jean-Baptiste Marie and CTO Nicolas Bourg, Abbelight develops microscopy and nanoscopy (SMLM) platforms that combine chemistry, optics, and data analysis, allowing researchers in public institutes and biotech companies to study complex biological mechanisms at the nanoscale.

Read Also - London’s Engitix Raises €21M To Advance ECM-Focused Cancer And Fibrosis Therapies

“Big things happen at the nanoscale - and Abbelight enables researchers to visualize precise sub-cellular structures like never before”, said Daniella Kranjac, Founding General Partner at AVANT BIO. “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accelerate discovery and drive innovation across life sciences”.

AVANT BIO specializes in growth-stage investments in enabling technologies, TechBio, and HealthTech, supporting companies that accelerate innovation in therapeutics discovery, development, and manufacturing.

“This is an exciting moment for Abbelight. The funding accelerates our commercial expansion and allows us to continue delivering best-in-class support to our 100+ installed base”, said Jean-Baptiste Marie, CEO and co-founder. “AVANT BIO’s support will be key to driving innovation and adoption across the broader bioindustry, including biopharma, biotech, and CROs”.

About AVANT BIO

AVANT BIO is a growth equity firm investing in enabling technologies that drive the future of therapeutics. Focused on TechBio and HealthTech, the firm supports companies at various stages to accelerate innovation, create value, and unlock the full potential of technologies shaping drug discovery, development and manufacturing.